Karolinska Development AB - Class B

OTCPK:KDEVF (Sweden)   Class B
$ 0.26 0 (0%) 07:08 PM EST
13.45
P/B:
0.35
Market Cap:
$ 40.98M
Enterprise V:
$ 33.95M
Volume:
-
Avg Vol (2M):
-
Also Trade In:
Volume:
-
Avg Vol (2M):
-
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for KDEVF ( Karolinska Development AB ) from 2018 to May 20 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Karolinska Development AB stock (KDEVF) PE ratio as of May 20 2024 is 13.45. More Details

Karolinska Development AB (KDEVF) PE Ratio (TTM) Chart

To

Karolinska Development AB (KDEVF) PE Ratio (TTM) Historical Data

Total 1231
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
Karolinska Development AB PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-05-21 23.4 2024-03-18 257.6
2024-05-20 23.4 2024-03-15 257.6
2024-05-17 23.4 2024-03-14 257.6
2024-05-16 23.4 2024-03-13 257.6
2024-05-15 23.4 2024-03-12 257.6
2024-05-14 23.4 2024-03-11 257.6
2024-05-13 23.4 2024-03-08 257.6
2024-05-10 23.4 2024-03-07 257.6
2024-05-09 23.4 2024-03-06 257.6
2024-05-08 23.4 2024-03-05 257.6
2024-05-07 23.4 2024-03-04 257.6
2024-05-06 23.4 2024-03-01 257.6
2024-05-03 23.4 2024-02-29 257.6
2024-05-02 23.4 2024-02-28 257.6
2024-05-01 23.4 2024-02-27 257.6
2024-04-30 23.4 2024-02-26 257.6
2024-04-29 23.4 2024-02-23 257.6
2024-04-26 23.4 2024-02-22 257.6
2024-04-25 23.4 2024-02-21 257.6
2024-04-24 23.4 2024-02-20 257.6
2024-04-23 23.4 2024-02-16 257.6
2024-04-22 23.4 2024-02-15 257.6
2024-04-19 23.4 2024-02-14 257.6
2024-04-18 23.4 2024-02-13 257.6
2024-04-17 23.4 2024-02-12 257.6
2024-04-16 23.4 2024-02-09 257.6
2024-04-15 23.4 2024-02-08 257.6
2024-04-12 23.4 2024-02-07 257.6
2024-04-11 23.4 2024-02-06 257.6
2024-04-10 23.4 2024-02-05 257.6
2024-04-09 23.4 2024-02-02 257.6
2024-04-08 23.4 2024-02-01 257.6
2024-04-05 23.4 2024-01-31 257.6
2024-04-04 23.4 2024-01-30 257.6
2024-04-03 23.4 2024-01-29 257.6
2024-04-02 23.4 2024-01-26 257.6
2024-04-01 23.4 2024-01-25 257.6
2024-03-28 23.4 2024-01-24 257.6
2024-03-27 257.6 2024-01-23 257.6
2024-03-26 257.6 2024-01-22 257.6
2024-03-25 257.6 2024-01-19 257.6
2024-03-22 257.6 2024-01-18 257.6
2024-03-21 257.6 2024-01-17 257.6
2024-03-20 257.6 2024-01-16 257.6
2024-03-19 257.6 2024-01-12 257.6

Karolinska Development AB (KDEVF) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
Karolinska Development AB is a life science investment company. It is focused on identifying breakthrough medical innovations in the Nordic region. It selects commercially attractive medical innovations, develops innovations to the stage where the return on investment can be achieved, and commercializes the innovations through the sale of companies or out-licensing of products. The company focused on profiles namely Aprea Therapeutics; Modus Therapeutics; BioArctic; Umecrine Cognition; and OssDsign.